Rhipicephalus microplus é um ectoparasito hematófago amplamente distribuído em regiões tropicais e subtropicais. Sua infestação compromete a saúde bovina, causando anemia, reduzindo a produção de leite e impactando no bem-estar geral animal, além de atuar como vetor de patógenos da tristeza parasitária bovina. No Brasil, estima-se que o parasito gere perdas anuais de US3,2bilho~es.Emboraocontrolesejamajoritariamentebaseadonousodeacaricidassinteˊticos,ousoindiscriminadofavoreceosurgimentodepopulac\co~esresistentesegeraimpactosambientais.Nessecenaˊrio,odesenvolvimentodevacinasseapresentacomoumaalternativapromissoraeabuscaporantıˊgenosprotetoresenvolveacaracterizac\ca~odeproteıˊnasdocarrapatoenvolvidasnarelac\ca~oparasito−hospedeiro.AparamiosinadeR.microplus(BmPRM)eˊumaproteıˊnacompesomolecularde102kDa,cujosilenciamentoge^nicocorrespondentereduziuaposturadeovoseaeclosa~odelarvas,sugerindopapelimportantenociclodevidadesteectoparasito.Emoutrosparasitos,eˊdemonstradoqueessaproteıˊnapossuipropriedadesimunomoduladoras,interagindocomanticorposecomponentesdosistemacomplemento.Essascaracterıˊsticasreforc\camejustificaminvestigac\co~esquantoaoseupotencialcomoantıˊgenovacinal.Esteestudoavaliouinsilicocaracterıˊsticasestruturais,funcionaiseimunesdaBmPRM,produziuepurificoudeformarecombinantetre^sformastruncadasdaBmPRMcorrespondentesassuasregio~esetestouoreconhecimentodiferencialdestasproteıˊnasfrenteasoroshiperimunes.Asclonagensdasseque^nciascodificadoresparaastre^sregio~esdaBmPRM,denominadasN−BmPRM(regia~oNterminal),Int−BmPRM(regia~ointerna)eC−BmPRM(regia~oC−terminal),foramfeitasemvetordeexpressa~oprocarioˊticoeasexpresso~esconduzidasemEscherichiacoli.Apartirdaincorporac\ca~odeumacaudadeseishistidinas,asproteıˊnasforampurificadasporcromatografiadeafinidadeusandocolunacarregadacomnıˊquel.AsproteıˊnasrecombinantesforamutilizadasemensaiosELISAcomsorodebovinoimunizadocomrBmPRMecoelhoimunizadocomextratodegla^ndulasalivardefe^measadultasparcialmenteingurgitadas(partenoˊginas),ondeossorosdestesanimaisforamadsorvidoscomasporc\co~esrecombinantesdaproteıˊna.Asadsorc\co~escomrC−BmPRMerInt−BmPRMremoveramquantidadessignificativas(30 3.2 billion. Although control strategies primarily rely on the use of synthetic acaricides, their indiscriminate application promotes the emergence of resistant populations and poses environmental risks. In this context, vaccine development represents a promising alternative, and the search for protective antigens involves the characterization of tick proteins associated with the parasite–host relationship. R. microplus paramyosin (BmPRM) is a 102-kDa protein whose gene silencing has been shown to reduce egg laying and larval hatching, suggesting its critical role in the parasite’s life cycle. In other parasites, this protein has demonstrated immunomodulatory properties, including interactions with antibodies and components of the complement system. These features support further investigation of its potential as a vaccine antigen.This study evaluated the structural, functional, and immunological characteristics of BmPRM through in silico analyses. Three truncated forms of BmPRM, corresponding to different regions of the protein, were also recombinantly produced and purified. The coding sequences for the three regions — N-BmPRM (N-terminal region), Int-BmPRM (internal region), and C-BmPRM (C-terminal region) — were cloned into a prokaryotic expression vector and expressed in Escherichia coli. A six-histidine tag was added to each construct, and the recombinant proteins were purified by affinity chromatography using a nickel-loaded column. The recombinant proteins were employed in ELISA assays using a bovine serum immunized with rBmPRM and a rabbit serum immunized with salivary gland extract from partially engorged adult females. The sera from these animals were adsorbed using the recombinant proteins. Adsorption with rC-BmPRM and rInt-BmPRM removed significant amounts of antibodies (30% - 40%), suggesting that these regions are the main targets of immune recognition under the conditions used. These findings highlight the immunogenic potential of paramyosin and reinforce the need for further studies to assess its applicability as a vaccine candidate against R. microplus